EQRx (NASDAQ: EQRX) operates as a biotechnology company focusing on re-engineering the processes from drug discovery to patient delivery. The company develops and delivers medicines for prevalent disease areas. It was founded in 2019 and is based in Cambridge, Massachusetts.
Research containing EQRx
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned EQRx in 1 CB Insights research brief, most recently on Jul 14, 2023.
Expert Collections containing EQRx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
EQRx is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
Latest EQRx News
Sep 27, 2023
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders September 27, 2023 at 01:41 pm EDT Share Shareholder rights law firm Robbins LLP is investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders. If you would like more information about our investigation of EQRx's misconduct, click here. EQRx, Inc. (EQRX) May Have Engaged in a Conflicted SPAC Process EQRx International, Inc. completed a business combination with CM Life Sciences III Inc. on December 17, 2021, and now operates as EQRx, Inc. In April, Corvex Management LP agreed to pay the SEC $1 million to settle allegations that the investment advisor did not properly disclose conflicts of interests involving certain SPACs. The SEC alleged that from July 2020 through January 2021, Corvex personnel were involved in forming three SPACs know as CM Life Sciences Inc., CM Life Sciences II Inc., and CM Life Sciences III Inc. (now EQRx, Inc.). Individuals supervised by Corvex owned about half of the sponsors of the three SPACs. Because of their ownership interests, Corvex personnel were entitled to receive a portion of the SPAC sponsor compensation once the SPACs completed their business combinations. The SEC alleged that Corvex personnel thus had financial incentives to push the firm's advisory clients to make SPAC-related investments to ensure the three SPACs completed business combinations. The agency said that Corvex caused its advisory clients to participate in $122.5 million worth of private investment in public equity transactions, or PIPE transactions, in connection with the three SPACs' ultimate business combinations. Corvex didn't disclose the conflicts of interest April 2021 — after the three SPACs had consummated their initial public offerings. Corvex founder Keith A. Meister and CM Life Sciences Holdings, the sponsor of one of the SPACs mentioned in the SEC's order, were hit with an investor suit in February in Delaware Chancery Court, alleging they made misleading disclosures in the lead-up to the take-public merger and immediate value plunge of clinical data and genomics company Sema4 Holdings in July 2021. What Now: EQRx, Inc. shareholders have legal options. If you own shares of EQRx or have incurred a recent significant loss in the stock, contact us for more information about your rights. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas, Jr.
EQRx Frequently Asked Questions (FAQ)
When was EQRx founded?
EQRx was founded in 2019.
Where is EQRx's headquarters?
EQRx's headquarters is located at 50 Hampshire Street, Cambridge.
What is EQRx's latest funding round?
EQRx's latest funding round is Acq - Pending.
How much did EQRx raise?
EQRx raised a total of $700M.
Who are the investors of EQRx?
Investors of EQRx include Revolution Medicines, CM Life Sciences III, Google Ventures, Andreessen Horowitz, Section 32 and 7 more.
Who are EQRx's competitors?
Competitors of EQRx include Entelos and 5 more.
Compare EQRx to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
Konova offers anti-obesity drug development
SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market and inhibits MetAP2 - an enzyme that independent research has shown to be key to tumor growth, proliferation, and metastasis. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.
Core Dynamics is a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature.